FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments on the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Immune Therapeutics Inc. signed an agreement with KRS ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果